GM-CSF: A Promising Target in Inflammation and Autoimmunity

Ujawnienie

Pracodawca K.M.-C. L., A.A.A i J.A.H., University of Melbourne, udzielił licencji na opatentowaną technologię dotyczącą terapeutycznego ukierunkowania GM-CSF firmie MorphoSys AG, Niemcy.

1. Burgess AW, Metcalf D. The nature and action of granulocyte-macrophage colony stimulating factors. Blood. 1980;56(6):947-958. doi:10.1182/blood.V56.6.947.947

2. Hamilton JA, Cook AD, Tak PP. Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nat Rev Drug Discov. 2016;16(1):53-70.

3. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8(7):533-544. doi:10.1038/nri2356

4. Wicks IP, Roberts AW, Targeting GM. CSF in inflammatory diseases. Nat Rev Rheumatol. 2016;12(1):37–48. doi:10.1038/nrrheum.2015.161

5. Becher B, Tugues S, Greter M. GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity. 2016;45(5):963-973. doi:10.1016/j.immuni.2016.10.026

6. Hamilton JA. GM-CSF in inflammation. J Exp Med. 2020;217(1):e20190945.

7. Hansen G, Hercus TR, McClure BJ, et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell. 2008;134(3):496-507. doi:10.1016/j.cell.2008.05.053

8. Lehtonen A, Matikainen S, Miettinen M, Julkunen I. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J Leukoc Biol. 2002;71(3):511-519.

9. Perugini M, Brown AL, Salerno DG, et al. Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit. Blood. 2010;115(16):3346–3353. doi:10.1182/blood-2009-08-235846

10. Achuthan A, Aslam ASM, Nguyen Q, et al. Glucocorticoids promote apoptosis of proinflammatory monocytes by inhibiting ERK activity. Cell Death Dis. 2018;9(3):267. doi:10.1038/s41419-018-0332-4

11. van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood. 2012;119(15):3383–3393.

12. Gao Y, Nish SA, Jiang R, et al. Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells. Immunity. 2013;39(4):722–732. doi:10.1016/j.immuni.2013.08.028

13. Inaba K, Yashiro T, Hiroki I, Watanabe R, Kasakura K, Nishiyama C. Dual roles of PU.1 in the expression of PD-L2: direct transactivation with IRF4 and indirect epigenetic regulation. J Immunol. 2020;205(3):822–829.

14. Lehtonen A, Veckman V, Nikula T, et al. Differential expression of IFN regulatory factor 4 gene in human monocyte-derived dendritic cells and macrophages. J Immunol. 2005;175(10):6570–6579. doi:10.4049/jimmunol.175.10.6570

15. Williams JW, Tjota MY, Clay BS, et al. Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. Nat Commun. 2013;4(1):2990. doi:10.1038/ncomms3990

16. Yashiro T, Yamaguchi M, Watanuki Y, Kasakura K, Nishiyama C. The transcription factors PU.1 and IRF4 determine dendritic cell-specific expression of RALDH2. J Immunol. 2018;201(12):3677–3682. doi:10.4049/jimmunol.1800492

17. Achuthan A, Cook AD, Lee MC, et al. Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation. J Clin Invest. 2016;126(9):3453-3466. doi:10.1172/JCI87828

18. Lee MC, Lacey DC, Fleetwood AJ, Achuthan A, Hamilton JA, Cook AD. GM-CSF- and IRF4-dependent signaling can regulate myeloid cell numbers and the macrophage phenotype during inflammation. J Immunol. 2019;202(10):3033–3040. doi:10.4049/jimmunol.1801549

19. Krausgruber T, Blazek K, Smallie T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 2011;12(3):231-238. doi:10.1038/ni.1990

20. Weiss M, Blazek K, Byrne AJ, Perocheau DP, Udalova IA. IRF5 is a specific marker of inflammatory macrophages in vivo. Mediators Inflamm. 2013;2013:245804. doi:10.1155/2013/245804

21. Ahyi AN, Chang HC, Dent AL, Nutt SL, Kaplan MH. IFN regulatory factor 4 regulates the expression of a subset of Th2 cytokines. J Immunol. 2009;183(3):1598–1606. doi:10.4049/jimmunol.0803302

22. Satoh T, Takeuchi O, Vandenbon A, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol. 2010;11(10):936-944. doi:10.1038/ni.1920

23. Honma K, Udono H, Kohno T, et al. Interferon regulatory factor 4 negatively regulates the production of proinflammatory cytokines by macrophages in response to LPS. Proc Natl Acad Sci U S A. 2005;102(44):16001-16006. doi:10.1073/pnas.0504226102

24. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A. 1994;91(12):5592-5596. doi:10.1073/pnas.91.12.5592

25. Guilliams M, De Kleer I, Henri S, et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med. 2013;210(10):1977–1992. doi:10.1084/jem.20131199

26. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF reguluje różnicowanie makrofagów pęcherzykowych i odporność wrodzoną w płucach poprzez PU.1. Immunity. 2001;15(4):557–567. doi:10.1016/S1074-7613(01)00218-7

27. Reed JA, Ikegami M, Cianciolo ER, et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol. 1999;276(4):L556-563.

28. Trapnell BC, Nakata K, Bonella F, et al. Pulmonary alveolar proteinosis. Nat Rev Dis Primers. 2019;5(1):16. doi:10.1038/s41572-019-0066-3

29. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349(26):2527–2539.

30. Chen GH, Teitz-Tennenbaum S, Neal LM, et al. Local GM-CSF-dependent differentiation and activation of pulmonary dendritic cells and macrophages protect against progressive cryptococcal lung infection in mice. J Immunol. 2016;196(4):1810–1821. doi:10.4049/jimmunol.1501512

31. Huang FF, Barnes PF, Feng Y, et al. GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med. 2011;184(2):259–268. doi:10.1164/rccm.201012-2036OC

32. Todd EM, Ramani R, Szasz TP, Morley SC. Wziewny GM-CSF u noworodkowych myszy zapewnia trwałą ochronę przed bakteryjnym zapaleniem płuc. Sci Adv. 2019;5(8):eaax3387. doi:10.1126/sciadv.aax3387

33. McWilliams IL, Rajbhandari R, Nozell S, Benveniste E, Harrington LE. STAT4 controls GM-CSF production by both Th1 and Th17 cells during EAE. J Neuroinflammation. 2015;12(1):128. doi:10.1186/s12974-015-0351-3

34. O’Malley JT, Eri RD, Stritesky GL, et al. STAT4 isoforms differentially regulate Th1 cytokine production and the severity of inflammatory bowel disease. J Immunol. 2008;181(7):5062–5070. doi:10.4049/jimmunol.181.7.5062

35. Sheng W, Yang F, Zhou Y, et al. STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation. Cell Res. 2014;24(12):1387-1402. doi:10.1038/cr.2014.154

36. Noster R, Riedel R, Mashreghi MF, et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Transl Med. 2014;6(241):241ra280. doi:10.1126/scitranslmed.3008706

37. Eberl G, Colonna M, Di Santo JP, McKenzie AN. Komórki limfoidalne wrodzone. Innate lymphoid cells: a new paradigm in immunology. Science. 2015;348(6237):aaa6566. doi:10.1126/science.aaa6566

38. Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517(7534):293–301. doi:10.1038/nature14189

39. Louis C, Souza-Fonseca-Guimaraes F, Yang Y, et al. NK cell-derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS. J Exp Med. 2020;217:5.

40. Mortha A, Chudnovskiy A, Hashimoto D, et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science. 2014;343(6178):1249288. doi:10.1126/science.1249288

41. Pearson C, Thornton EE, McKenzie B, et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. Elife. 2016;5:e10066.

42. Castro-Dopico T, Fleming A, Dennison TW, et al. GM-CSF calibrates macrophage defense and wound healing programs during intestinal infection and inflammation. Cell Rep. 2020;32(1):107857. doi:10.1016/j.celrep.2020.107857

43. Al-Mossawi MH, Chen L, Fang H, et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nat Commun. 2017;8(1):1510. doi:10.1038/s41467-017-01771-2

44. Weber GF, Chousterman BG, Hilgendorf I, et al. Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis. J Exp Med. 2014;211(6):1243–1256. doi:10.1084/jem.20131471

45. Rauch PJ, Chudnovskiy A, Robbins CS, et al. Innate response activator B cells protect against microbial sepsis. Science. 2012;335(6068):597–601. doi:10.1126/science.1215173

46. Snapper CM, Moorman MA, Rosas FR, Kehry MR, Maliszewski CR, Mond JJ. IL-3 and granulocyte-macrophage colony-stimulating factor strongly induce Ig secretion by sort-purified murine B cell activated through the membrane Ig, but not the CD40, signaling pathway. J Immunol. 1995;154(11):5842–5850.

47. Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7(310):310ra166. doi:10.1126/scitranslmed.aab4176

48. Li R, Rezk A, Ghadiri M, et al. Dimethyl fumarate treatment mediates an anti-inflammatory shift in b cell subsets of patients with multiple sclerosis. J Immunol. 2017;198(2):691–698. doi:10.4049/jimmunol.1601649

49. Smith MD, Martin KA, Calabresi PA, Bhargava P. Dimethyl fumarate alters B-cell memory and cytokine production in MS patients. Ann Clin Transl Neurol. 2017;4(5):351-355. doi:10.1002/acn3.411

50. Hirota K, Hashimoto M, Ito Y, et al. Autoimmune Th17 cells induced synovial stromal and innate lymphoid cell secretion of the cytokine GM-CSF to initiate and augment autoimmune arthritis. Immunity. 2018;48(6):1220–1232e1225. doi:10.1016/j.immuni.2018.04.009

51. Stock AT, Hansen JA, Sleeman MA, McKenzie BS, Wicks IP. GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease. J Exp Med. 2016;213(10):1983–1998. doi:10.1084/jem.20151853

52. Chen G, Bracamonte-Baran W, Diny NL, et al. Sca-1(+) cardiac fibroblasts promote development of heart failure. Eur J Immunol. 2018;48(9):1522–1538. doi:10.1002/eji.201847583

53. Willart MA, Deswarte K, Pouliot P, et al. Interleukin-1alpha controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J Exp Med. 2012;209(8):1505–1517. doi:10.1084/jem.20112691

54. Sheih A, Parks WC, Ziegler SF. GM-CSF produced by the airway epithelium is required for sensitization to cockroach allergen. Mucosal Immunol. 2017;10(3):705–715.

55. Cakarova L, Marsh LM, Wilhelm J, et al. Macrophage tumor necrosis factor-alpha induces epithelial expression of granulocyte-macrophage colony-stimulating factor: impact on alveolar epithelial repair. Am J Respir Crit Care Med. 2009;180(6):521–532. doi:10.1164/rccm.200812-1837OC

56. Schuett J, Schuett H, Oberoi R, et al. NADPH oxidase NOX2 mediates TLR2/6-dependent release of GM-CSF from endothelial cells. FASEB J. 2017;31(6):2612-2624. doi:10.1096/fj.201600729R

57. Pare A, Mailhot B, Levesque SA, et al. IL-1beta umożliwia dostęp CNS do monocytów CCR2(hi) i generowanie patogennych komórek poprzez GM-CSF uwalniany przez komórki śródbłonka CNS. Proc Natl Acad Sci U S A. 2018;115(6):E1194-E1203. doi:10.1073/pnas.1714948115

58. Montanari E, Stojkovic S, Kaun C, et al. Interleukin-33 stymuluje produkcję GM-CSF i M-CSF przez ludzkie komórki śródbłonka. Thromb Haemost. 2016;116(2):317–327. doi:10.1160/TH15-12-0917

59. Hamilton JA, Anderson GP. GM-CSF biology. Growth Factors. 2004;22(4):225–231. doi:10.1080/08977190412331279881

60. Ribechini E, Hutchinson JA, Hergovits S, et al. Novel GM-CSF signals via IFN-gammaR/IRF-1 and AKT/mTOR license monocytes for suppressor function. Blood Adv. 2017;1(14):947-960. doi:10.1182/bloodadvances.2017006858

61. Lacey DC, Achuthan A, Fleetwood AJ, et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol. 2012;188(11):5752–5765. doi:10.4049/jimmunol.1103426

62. Collins HL, Bancroft GJ. Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of cryptococcus neoformans. Eur J Immunol. 1992;22(6):1447–1454. doi:10.1002/eji.1830220617

63. LeVine AM, Reed JA, Kurak KE, Cianciolo E, Whitsett JA. GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. J Clin Invest. 1999;103(4):563-569. doi:10.1172/JCI5212

64. Subramanian Vignesh K, Landero Figueroa JA, Porollo A, Caruso JA, Deepe GS Jr. Granulocyte macrophage-colony stimulating factor induced Zn sequestration enhances macrophage superoxide and limits intracellular pathogen survival. Immunity. 2013;39(4):697–710. doi:10.1016/j.immuni.2013.09.006

65. McDermott AJ, Frank CR, Falkowski NR, McDonald RA, Young VB, Huffnagle GB. Role of GM-CSF in the inflammatory cytokine network that regulates neutrophil influx into the colonic mucosa during clostridium difficile infection in mice. Gut Microbes. 2014;5(4):476-484. doi:10.4161/gmic.29964

66. Darrieutort-Laffite C, Boutet MA, Chatelais M, et al. IL-1beta and TNFalpha promote monocyte viability through the induction of GM-CSF expression by rheumatoid arthritis synovial fibroblasts. Mediators Inflamm. 2014;2014:241840. doi:10.1155/2014/241840

67. Dabritz J, Weinhage T, Varga G, et al. Reprogramming of monocytes by GM-CSF contributes to regulatory immune functions during intestinal inflammation. J Immunol. 2015;194(5):2424–2438. doi:10.4049/jimmunol.1401482

68. Sorgi CA, Rose S, Court N, et al. GM-CSF priming drives bone marrow-derived macrophages to a pro-inflammatory pattern and downmodulates PGE2 in response to TLR2 ligands. PLoS One. 2012;7(7):e40523. doi:10.1371/journal.pone.0040523

69. Lendemans S, Rani M, Selbach C, Kreuzfelder E, Schade FU, Flohe S. GM-CSF priming of human monocytes is dependent on ERK1/2 activation. J Endotoxin Res. 2006;12(1):10-20. doi:10.1177/09680519060120010201

70. Jablonska E, Kiluk M, Markiewicz W, Jablonski J. Priming effects of GM-CSF, IFN-gamma and TNF-alpha on human neutrophil inflammatory cytokine production. Melanoma Res. 2002;12(2):123-128. doi:10.1097/00008390-200204000-00004

71. Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol. 2007;178(8):5245–5252. doi:10.4049/jimmunol.178.8.5245

72. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20. doi:10.1016/j.immuni.2014.06.008

73. King IL, Kroenke MA, Segal BM. GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J Exp Med. 2010;207(5):953–961. doi:10.1084/jem.20091844

74. Daro E, Pulendran B, Brasel K, et al. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol. 2000;165(1):49–58. doi:10.4049/jimmunol.165.1.49

75. Suzuki H, Katayama N, Ikuta Y, et al. Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes. Am J Hematol. 2004;75(4):179-189. doi:10.1002/ajh.20010

76. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693–1702. doi:10.1084/jem.176.6.1693

77. Conti L, Gessani S. GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology. 2008;213(9–10):859–870. doi:10.1016/j.imbio.2008.07.017

78. Helft J, Bottcher J, Chakravarty P, et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. Immunity. 2015;42(6):1197–1211. doi:10.1016/j.immuni.2015.05.018

79. Louis C, Cook AD, Lacey D, et al. Specific contributions of CSF-1 and GM-CSF to the dynamics of the mononuclear phagocyte system. J Immunol. 2015;195(1):134–144. doi:10.4049/jimmunol.1500369

80. Lee KM, Jarnicki A, Achuthan A, et al. CCL17 w zapaleniu i bólu. J Immunol. 2020;205(1):213–222. doi:10.4049/jimmunol.2000315

81. Ko HJ, Brady JL, Ryg-Cornejo V, et al. GM-CSF-responsive monocyte-derived dendritic cells are pivotal in Th17 pathogenesis. J Immunol. 2014;192(5):2202–2209. doi:10.4049/jimmunol.1302040

82. Greter M, Helft J, Chow A, et al. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity. 2012;36(6):1031–1046. doi:10.1016/j.immuni.2012.03.027

83. Reynolds G, Gibbon JR, Pratt AG, et al. Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. Ann Rheum Dis. 2016;75(5):899–907. doi:10.1136/annrheumdis-2014-206578

84. Campbell IK, van Nieuwenhuijze A, Segura E, et al. Differentiation of inflammatory dendritic cells is mediated by NF-kappaB1-dependent GM-CSF production in CD4 T cells. J Immunol. 2011;186(9):5468–5477. doi:10.4049/jimmunol.1002923

85. Hamilton JA. GM-CSF-dependent inflammatory pathways. Front Immunol. 2019;10:2055. doi:10.3389/fimmu.2019.02055

86. Bourdely P, Anselmi G, Vaivode K, et al. Transcriptional and functional analysis of CD1c(+) human dendritic cells identifies a CD163(+) subset priming CD8(+)CD103(+) T cells. Immunity. 2020;53(2):335–352e338. doi:10.1016/j.immuni.2020.06.002

87. Sonderegger I, Iezzi G, Maier R, Schmitz N, Kurrer M, Kopf M. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med. 2008;205(10):2281–2294. doi:10.1084/jem.20071119

88. Yong KL, Rowles PM, Patterson KG, Linch DC. Granulocyte-macrophage colony-stimulating factor induces neutrophil adhesion to pulmonary vascular endothelium in vivo: role of beta 2 integrins. Blood. 1992;80(6):1565–1575. doi:10.1182/blood.V80.6.1565.1565

89. Sakagami T, Uchida K, Suzuki T, et al. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med. 2009;361(27):2679–2681. doi:10.1056/NEJMc0904077

90. Wright HL, Thomas HB, Moots RJ, Edwards SW. RNA-seq ujawnia aktywację zarówno wspólnych, jak i specyficznych dla cytokin szlaków po primingu neutrofili. PLoS One. 2013;8(3):e58598. doi:10.1371/journal.pone.0058598

91. Yousefi S, Mihalache C, Kozlowski E, Schmid I, Simon HU. Viable neutrophils release mitochondrial DNA to create neutrophil extracellular traps. Cell Death Differ. 2009;16(11):1438–1444. doi:10.1038/cdd.2009.96

92. Alferink J, Lieberam I, Reindl W, et al. Compartmentalized production of CCL17 in vivo: strong inducibility in peripheral dendritic cells contrasts selective absence from the spleen. J Exp Med. 2003;197(5):585–599. doi:10.1084/jem.20021859

93. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2001;194(6):847–853. doi:10.1084/jem.194.6.847

94. Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. Int Immunol. 2015;27(1):11-20. doi:10.1093/intimm/dxu079

95. Russo RC, Savino B, Mirolo M, et al. The atypical chemokine receptor ACKR2 drives pulmonary fibrosis by tuning influx of CCR2(+) and CCR5(+) IFNgamma-producing gammadeltaT cells in mice. Am J Physiol Lung Cell Mol Physiol. 2018;314(6):L1010-L1025. doi:10.1152/ajplung.00233.2017

96. Hsu AT, Lupancu TJ, Lee MC, et al. Epigenetyczna i transkrypcyjna regulacja indukowanej przez IL4 produkcji CCL17 w ludzkich monocytach i makrofagach myszy. J Biol Chem. 2018;293(29):11415–11423. doi:10.1074/jbc.RA118.002416

97. Lee KM, Prasad V, Achuthan A, Fleetwood AJ, Hamilton JA, Cook AD. Targeting GM-CSF for collagenase-induced osteoarthritis pain and disease in mice. Osteoarthritis Cartilage. 2020;28(4):486–491. doi:10.1016/j.joca.2020.01.012

98. Lee MC, Saleh R, Achuthan A, et al. CCL17 blockade as a therapy for osteoarthritis pain and disease. Arthritis Res Ther. 2018;20(1):62. doi:10.1186/s13075-018-1560-9

99. Cook AD, Lee MC, Saleh R, et al. TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17. JCI Insight. 2018;3(6):6. doi:10.1172/jci.insight.99249

100. Burmester GR, McInnes IB, Kremer JM, et al. Mavrilimumab, w pełni ludzkie przeciwciało monoklonalne receptora alfa czynnika stymulującego kolonie granulocytów-makrofagów: długoterminowe bezpieczeństwo i skuteczność u pacjentów z reumatoidalnym zapaleniem stawów. Arthritis Rheumatol. 2018;70(5):679–689.

101. Cook AD, Christensen AD, Tewari D, McMahon SB, Hamilton JA. Cytokiny immunologiczne i ich receptory w bólu zapalnym. Trends Immunol. 2018;39(3):240–255. doi:10.1016/j.it.2017.12.003

102. Thakur M, Crow M, Richards N, et al. Defining the nociceptor transcriptome. Front Mol Neurosci. 2014;7:87. doi:10.3389/fnmol.2014.00087

103. Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci. 2001;21(14):5027–5035. doi:10.1523/JNEUROSCI.21-14-05027.2001

104. Li CL, Li KC, Wu D, et al. Somatosensory neuron types identified by high-coverage single-cell RNA-sequencing and functional heterogeneity. Cell Res. 2016;26(1):83-102. doi:10.1038/cr.2015.149

105. Weber C, Meiler S, Doring Y, et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest. 2011;121(7):2898-2910. doi:10.1172/JCI44925

106. Heiseke AF, Faul AC, Lehr HA, et al. CCL17 promotes intestinal inflammation in mice and counteracts regulatory T cell-mediated protection from colitis. Gastroenterology. 2012;142(2):335–345. doi:10.1053/j.gastro.2011.10.027

107. Cook AD, Pobjoy J, Steidl S, et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res Ther. 2012;14(5):R199. doi:10.1186/ar4037

108. Cook AD, Pobjoy J, Sarros S, et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain. Ann Rheum Dis. 2013;72(2):265–270.

109. Stosser S, Schweizerhof M, Kuner R. Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions. J Mol Med (Berl). 2011;89(4):321–329.

110. Schweizerhof M, Stosser S, Kurejova M, et al. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med. 2009;15(7):802-807. doi:10.1038/nm.1976

111. Ridwan S, Bauer H, Frauenknecht K, von Pein H, Sommer CJ. Distribution of granulocyte-monocyte colony-stimulating factor and its receptor alpha-subunit in the adult human brain with specific reference to Alzheimer’s disease. J Neural Transm (Vienna). 2012;119(11):1389–1406. doi:10.1007/s00702-012-0794-y

112. Bali KK, Venkataramani V, Satagopam VP, Gupta P, Schneider R, Kuner R. Transcriptional mechanisms underlying sensitization of peripheral sensory neurons by granulocyte-/granulocyte-macrophage colony stimulating factors. Mol Pain. 2013;9:48. doi:10.1186/1744-8069-9-48

113. Nicol LSC, Thornton P, Hatcher JP, et al. Centralne hamowanie czynnika stymulującego kolonie granulocytów-makrofagów jest analgetyczne w eksperymentalnym bólu neuropatycznym. Pain. 2018;159(3):550–559. doi:10.1097/j.pain.0000000000001130

114. Zhang F, Wang Y, Liu Y, et al. Transcriptional regulation of voltage-gated sodium channels contributes to GM-CSF-induced pain. J Neurosci. 2019;39(26):5222–5233. doi:10.1523/JNEUROSCI.2204-18.2019

115. Tewari D, Cook AD, Lee MC, et al. Granulocyte-macrophage colony stimulating factor as an indirect mediator of nociceptor activation and pain. J Neurosci. 2020;40(11):2189–2199. doi:10.1523/JNEUROSCI.2268-19.2020

116. Schabitz WR, Kruger C, Pitzer C, et al. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab. 2008;28(1):29–43. doi:10.1038/sj.jcbfm.9600496

117. Kelso ML, Elliott BR, Haverland NA, Mosley RL, Gendelman HE. Granulocyte-macrophage colony stimulating factor exerts protective and immunomodulatory effects in cortical trauma. J Neuroimmunol. 2015;278:162–173. doi:10.1016/j.jneuroim.2014.11.002

118. Xu WD, Firestein GS, Taetle R, Kaushansky K, Zvaifler NJ. Cytokiny w przewlekłym zapalnym zapaleniu stawów. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest. 1989;83(3):876-882. doi:10.1172/JCI113971

119. Fiehn C, Wermann M, Pezzutto A, Hufner M, Heilig B. Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy. Z Rheumatol. 1992;51(3):121–126.

120. Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, Stern AC, Vellenga E. Correction of granulocytopenia in Felty’s syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood. 1989;74(8):2769–2770. doi:10.1182/blood.V74.8.2769.2769

121. Okada Y, Terao C, Ikari K, et al. Meta-analysis identyfikuje dziewięć nowych loci związanych z reumatoidalnym zapaleniem stawów w populacji japońskiej. Nat Genet. 2012;44(5):511-516. doi:10.1038/ng.2231

122. Shi H, Chen L, Ridley A, et al. GM-CSF primes proinflammatory monocyte responses in ankylosing spondylitis. Front Immunol. 2020;11:1520. doi:10.3389/fimmu.2020.01520

123. Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol. 1998;161(7):3639–3644.

124. Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 2001;3(5):293-298. doi:10.1186/ar318

125. Bystrom J, Clanchy FI, Taher TE, et al. Response to treatment with TNFalpha inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF(+) T lymphocytes. Clin Rev Allergy Immunol. 2017;53(2):265-276. doi:10.1007/s12016-017-8610-y

126. van Helvoort EM, Eijkelkamp N, Lafeber F, Mastbergen SC. Expression of granulocyte macrophage-colony stimulating factor and its receptor in the synovium of osteoarthritis patients is negatively correlated with pain. Rheumatology (Oxford). 2020. doi:10.1093/rheumatology/keaa199

127. Berenbaum F, Rajzbaum G, Amor B, Toubert A. Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies. Eur Cytokine Netw. 1994;5(1):43-46.

128. Moradi B, Rosshirt N, Tripel E, et al. Unicompartmental and bicompartmental knee osteoarthritis show different patterns of mononuclear cell infiltration and cytokine release in the affected joints. Clin Exp Immunol. 2015;180(1):143-154. doi:10.1111/cei.12486

129. Klein-Wieringa IR, de Lange-brokaar BJ, Yusuf E, et al. Inflammatory cells in patients with endstage knee osteoarthritis: a comparison between the synovium and the infrapatellar fat pad. J Rheumatol. 2016;43(4):771–778. doi:10.3899/jrheum.151068

130. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005;64(9):1263–1267. doi:10.1136/ard.2004.025270

131. Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol. 2019;41(3):283–297.

132. Haak S, Croxford AL, Kreymborg K, et al. IL-17A i IL-17F nie przyczyniają się w sposób istotny do autoimmunologicznego neurozapalenia u myszy. J Clin Invest. 2009;119(1):61-69.

133. Codarri L, Gyulveszi G, Tosevski V, et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol. 2011;12(6):560-567. doi:10.1038/ni.2027

134. El-Behi M, Ciric B, Dai H, et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol. 2011;12(6):568-575. doi:10.1038/ni.2031

135. Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol. 2007;178(1):39–48. doi:10.4049/jimmunol.178.1.39

136. Gonzalez H, Pacheco R. T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation. 2014;11(1):201. doi:10.1186/s12974-014-0201-8

137. Parajuli B, Sonobe Y, Kawanokuchi J, et al. GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia. J Neuroinflammation. 2012;9:268.

138. King IL, Dickendesher TL, Segal BM. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood. 2009;113(14):3190–3197. doi:10.1182/blood-2008-07-168575

139. Vogel DY, Kooij G, Heijnen PD, et al. GM-CSF promotes migration of human monocytes across the blood brain barrier. Eur J Immunol. 2015;45(6):1808–1819. doi:10.1002/eji.201444960

140. Vogel DY, Vereyken EJ, Glim JE, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013;10(1):35. doi:10.1186/1742-2094-10-35

141. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707–717. doi:10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q

142. Duncker PC, Stoolman JS, Huber AK, Segal BM. GM-CSF promuje przewlekłą niepełnosprawność w doświadczalnym autoimmunologicznym zapaleniu mózgu i rdzenia poprzez zmianę składu komórek naciekających ośrodkowy układ nerwowy, ale jest zbędny do indukcji choroby. J Immunol. 2018;200(3):966–973.

143. McQualter JL, Darwiche R, Ewing C, et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med. 2001;194(7):873–882. doi:10.1084/jem.194.7.873

144. Carrieri PB, Provitera V, De Rosa T, Tartaglia G, Gorga F, Perrella O. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol Immunotoxicol. 1998;20(3):373–382. doi:10.3109/08923979809034820

145. Perrella O, Carrieri PB, De Mercato R, Buscaino GA. Markers of activated T lymphocytes and T cell receptor gamma/delta+ in patients with multiple sclerosis. Eur Neurol. 1993;33(2):152-155. doi:10.1159/000116923

146. Aharoni R, Eilam R, Schottlender N, et al. Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis. J Neuroimmunol. 2020;345:577281. doi:10.1016/j.jneuroim.2020.577281

147. Ananthakrishnan AN. Epidemiologia i czynniki ryzyka IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–217. doi:10.1038/nrgastro.2015.34

148. Marks DJ, Rahman FZ, Sewell GW, Segal AW. Crohn’s disease: an immune deficiency state. Clin Rev Allergy Immunol. 2010;38(1):20–31. doi:10.1007/s12016-009-8133-2

149. Griseri T, McKenzie BS, Schiering C, Powrie F. Dysregulated hematopoietic stem and progenitor cell activity promotes interleukin-23-driven chronic intestinal inflammation. Immunity. 2012;37(6):1116–1129. doi:10.1016/j.immuni.2012.08.025

150. Griseri T, Arnold IC, Pearson C, et al. Granulocyte macrophage colony-stimulating factor-activated eosinophils promote interleukin-23 driven chronic colitis. Immunity. 2015;43(1):187–199. doi:10.1016/j.immuni.2015.07.008

151. Xu Y, Hunt NH, Bao S. The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation. Cell Res. 2008;18(12):1220-1229. doi:10.1038/cr.2008.310

152. Dabritz J. Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn’s disease. Am J Physiol Gastrointest Liver Physiol. 2014;306(6):G455-465. doi:10.1152/ajpgi.00409.2013

153. Bernasconi E, Favre L, Maillard MH, et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis. 2010;16(3):428-441. doi:10.1002/ibd.21072

154. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn’s disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002;360(9344):1478–1480. doi:10.1016/S0140-6736(02)11437-1

155. Gathungu G, Zhang Y, Tian X, et al. Impaired granulocyte-macrophage colony-stimulating factor bioactivity accelerates surgical recurrence in ileal Crohn’s disease. World J Gastroenterol. 2018;24(5):623–630. doi:10.3748/wjg.v24.i5.623

156. Denson LA, Jurickova I, Karns R, et al. Genetic and transcriptomic variation linked to neutrophil granulocyte-macrophage colony-stimulating factor signaling in pediatric crohn’s disease. Inflamm Bowel Dis. 2019;25(3):547-560. doi:10.1093/ibd/izy265

157. Atzeni F, Gerardi MC, Barilaro G, Masala IF, Benucci M, Sarzi-Puttini P. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018;14(1):69–82. doi:10.1080/1744666X.2018.1411190

158. Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 2003;426(6965):454–460. doi:10.1038/nature02119

159. Guerard S, Boieri M, Hultqvist M, Holmdahl R, Wing K. The SKG mutation in ZAP-70 also confers arthritis susceptibility in C57 black mouse strains. Scand J Immunol. 2016;84(1):3-11. doi:10.1111/sji.12438

160. Benham H, Rehaume LM, Hasnain SZ, et al. Interleukin-23 mediates the intestinal response to microbial beta-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol. 2014;66(7):1755-1767. doi:10.1002/art.38638

161. Kwon OC, Lee EJ, Chang EJ, et al. IL-17A(+)GM-CSF(+) neutrophils are the major infiltrating cells in interstitial lung disease in an autoimmune arthritis model. Front Immunol. 2018;9:1544. doi:10.3389/fimmu.2018.01544

162. Shiomi A, Usui T, Ishikawa Y, Shimizu M, Murakami K, Mimori T. GM-CSF, ale nie IL-17 jest krytyczny dla rozwoju ciężkiej śródmiąższowej choroby płuc u myszy SKG. J Immunol. 2014;193(2):849–859. doi:10.4049/jimmunol.1303255

163. Chen YT, Hsu H, Lin CC, et al. Inflammatory macrophages switch to CCL17-expressing phenotype and promote peritoneal fibrosis. J Pathol. 2020;250(1):55-66. doi:10.1002/path.5350

164. Son BK, Sawaki D, Tomida S, et al. Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma. Nat Commun. 2015;6(1):6994. doi:10.1038/ncomms7994

165. Ye P, Chen W, Wu J, et al. GM-CSF contributes to aortic aneurysms resulting from SMAD3 deficiency. J Clin Invest. 2013;123(5):2317-2331. doi:10.1172/JCI67356

166. Nouri-Aria KT, Masuyama K, Jacobson MR, et al. Granulocyte/macrophage-colony stimulating factor in allergen-induced rhinitis: cellular localization, relation to tissue eosinophilia and influence of topical corticosteroid. Int Arch Allergy Immunol. 1998;117(4):248-254. doi:10.1159/000024019

167. Cates EC, Fattouh R, Wattie J, et al. Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism. J Immunol. 2004;173(10):6384–6392. doi:10.4049/jimmunol.173.10.6384

168. Yamashita N, Tashimo H, Ishida H, et al. Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). Cell Immunol. 2002;219(2):92–97. doi:10.1016/S0008-8749(02)00565-8

169. Ait Yahia S, Azzaoui I, Everaere L, et al. CCL17 production by dendritic cells is required for NOD1-mediated exacerbation of allergic asthma. Am J Respir Crit Care Med. 2014;189(8):899–908. doi:10.1164/rccm.201310-1827OC

170. Perros F, Hoogsteden HC, Coyle AJ, Lambrecht BN, Hammad H. Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation. Allergy. 2009;64(7):995–1002. doi:10.1111/j.1398-9995.2009.02095.x

171. Yuan L, Zhang X, Yang M, et al. Airway epithelial integrin beta4 suppresses allergic inflammation by decreasing CCL17 production. Clin Sci (Lond). 2020;134(13):1735–1749. doi:10.1042/CS20191188

172. Chen YL, Chiang BL. Targeting TSLP with shRNA alleviates airway inflammation and decreases epithelial CCL17 in a murine model of asthma. Mol Ther Nucleic Acids. 2016;5:e316. doi:10.1038/mtna.2016.29

173. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177–185. doi:10.1038/nature21363

174. Hotamisligil GS. Stan zapalny i zaburzenia metaboliczne. Nature. 2006;444(7121):860–867. doi:10.1038/nature05485

175. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–1830. doi:10.1172/JCI200319451

176. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–1808. doi:10.1172/JCI200319246

177. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175-184. doi:10.1172/JCI29881

178. Boi SK, Buchta CM, Pearson NA, et al. Obesity alters immune and metabolic profiles: new insight from obese-resistant mice on high-fat diet. Obesity (Silver Spring). 2016;24(10):2140–2149. doi:10.1002/oby.21620

179. Shaw OM, Pool B, Dalbeth N, Harper JL. Wpływ diety indukowanej otyłością na zapalny fenotyp makrofagów non-adipose-resident w modelu in vivo podagry. Rheumatology (Oxford). 2014;53(10):1901–1905. doi:10.1093/rheumatology/keu174

180. Kim DH, Sandoval D, Reed JA, et al. The role of GM-CSF in adipose tissue inflammation. Am J Physiol Endocrinol Metab. 2008;295(5):E1038–1046. doi:10.1152/ajpendo.00061.2008

181. Plubell DL, Fenton AM, Wilmarth PA, et al. GM-CSF driven myeloid cells in adipose tissue link weight gain and insulin resistance via formation of 2-aminoadipate. Sci Rep. 2018;8(1):11485. doi:10.1038/s41598-018-29250-8

182. Pamir N, Liu NC, Irwin A, et al. Granulocyte/macrophage colony-stimulating factor-dependent dendritic cells restrain lean adipose tissue expansion. J Biol Chem. 2015;290(23):14656–14667. doi:10.1074/jbc.M115.645820

183. Quail DF, Olson OC, Bhardwaj P, et al. Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF. Nat Cell Biol. 2017;19(8):974-987. doi:10.1038/ncb3578

184. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405–407. doi:10.1016/j.healun.2020.03.012

185. Moore JB, June CH. Zespół uwalniania cytokin w ciężkiej postaci COVID-19. Science. 2020;368(6490):473–474. doi:10.1126/science.abb8925

186. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-0

187. Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844. doi:10.1038/s41591-020-0901-9

188. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992–1000e1003. doi:10.1016/j.chom.2020.04.009

189. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217(6):6. doi:10.1084/jem.20200652

190. Tanaka T, Narazaki M, Kishimoto T. Immunoterapeutyczne implikacje blokady IL-6 dla burzy cytokinowej. Immunotherapy. 2016;8(8):959–970. doi:10.2217/imt-2016-0020

191. Sinha P, Matthay MA, Calfee CS. Is a „cytokine storm” relevant to COVID-19? JAMA Intern Med. 2020;180(9):1152. doi:10.1001/jamainternmed.2020.3313

192. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–1643. doi:10.1038/s41591-020-1051-9

193. Zhou Y, Fu B, Zheng X, et al. Patogenne komórki T i monocyty zapalne wzniecają burze zapalne u pacjentów z ciężką postacią COVID-19. Natl Sci Rev. 2020;7(6):998-1002. doi:10.1093/nsr/nwaa041

194. Sterner RM, Sakemura R, Cox MJ, et al. Hamowanie GM-CSF zmniejsza zespół uwalniania cytokin i neuroinflammation, ale zwiększa funkcję komórek CAR-T w ksenograftach. Blood. 2019;133(7):697–709. doi:10.1182/blood-2018-10-881722

195. Tugues S, Amorim A, Spath S, et al. Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. Sci Transl Med. 2018;10(469):469. doi:10.1126/scitranslmed.aat8410

196. Puljic R, Benediktus E, Plater-Zyberk C, et al. Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF. Eur J Pharmacol. 2007;557(2–3):230–235. doi:10.1016/j.ejphar.2006.11.023

197. De Alessandris S, Ferguson GJ, Dodd AJ, et al. Neutrophil GM-CSF receptor dynamics in acute lung injury. J Leukoc Biol. 2019;105(6):1183-1194. doi:10.1002/JLB.3MA0918-347R

198. Bozinovski S, Jones JE, Vlahos R, Hamilton JA, Anderson GP. Granulocyte/macrophage-colony-stimulating factor (GM-CSF) reguluje odporność wrodzoną płuc na lipopolisacharyd poprzez Akt/Erk aktywację NFkappa B i AP-1 in vivo. J Biol Chem. 2002;277(45):42808–42814. doi:10.1074/jbc.M207840200

199. Lang FM, Lee KM-C, Teijaro JR, Becher B, Hamilton JA. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. Nat Rev Immunol. 2020;20(8):507–514. doi:10.1038/s41577-020-0357-7

200. Bonaventura A, Vecchie A, Wang TS, et al. Targeting GM-CSF in COVID-19 pneumonia: rationale and strategies. Front Immunol. 2020;11:1625. doi:10.3389/fimmu.2020.01625

201. Behrens F, Tak PP, Ostergaard M, et al. MOR103, ludzkie przeciwciało monoklonalne przeciwko czynnikowi stymulującemu kolonie granulocytów-makrofagów, w leczeniu pacjentów z umiarkowanym reumatoidalnym zapaleniem stawów: wyniki randomizowanego, podwójnie ślepego, kontrolowanego placebo badania fazy Ib/IIa, z eskalacją dawki. Ann Rheum Dis. 2015;74(6):1058–1064. doi:10.1136/annrheumdis-2013-204816

202. Schett GBC, Berkowitz M, Davy K, et al. A Phase iia study of anti-GM-CSF antibody GSK3196165 in subjects with inflammatory hand osteoarthritis. Arthritis Rheumatol. 2018;70.

203. Patnaik MM, Sallman DA, Mangaonkar AA, et al. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020;136(7):909–913. doi:10.1182/blood.2019004352

204. Molfino NA, Kuna P, Leff JA, et al. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open. 2016;6(1):e007709. doi:10.1136/bmjopen-2015-007709

205. Temesgen Z, Assi M, Vergidis P, et al. Pierwsze kliniczne zastosowanie lenzilumabu w celu neutralizacji GM-CSF u pacjentów z ciężkim zapaleniem płuc COVID-19. medRxiv. 2020.

206. Tanaka S, Harada S, Hiramatsu N, Nakaya R, Kawamura M. Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumumab in healthy Japanese and Caucasian men. Int J Clin Pharmacol Ther. 2018;56(11):507-517. doi:10.5414/CP203235

207. Huizinga TW, Batalov A, Stoilov R, et al. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):53. doi:10.1186/s13075-017-1267-3

208. Taylor PC, Saurigny D, Vencovsky J, et al. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Res Ther. 2019;21(1):101.

209. Papp KA, Gooderham M, Jenkins R, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. Br J Dermatol. 2019;180(6):1352–1360. doi:10.1111/bjd.17195

210. Nair JR, Edwards SW, Moots RJ. Mavrilimumab, a human monoclonal GM-CSF receptor-alpha antibody for the management of rheumatoid arthritis: a novel approach to therapy. Expert Opin Biol Ther. 2012;12(12):1661–1668. doi:10.1517/14712598.2012.732062

211. Weinblatt ME, McInnes IB, Kremer JM, et al. A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis. Arthritis Rheumatol. 2018;70(1):49-59. doi:10.1002/art.40323

212. Burmester GR, McInnes IB, Kremer J, et al. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1020–1030. doi:10.1136/annrheumdis-2016-210624

213. De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020;2(8):E465–E473. doi:10.1016/S2665-9913(20)30170-3

214. McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. doi:10.1186/s13075-019-1964-1